Skip to main content
. 2022 Jun 20;54(1):1686–1700. doi: 10.1080/07853890.2022.2085881

Table 2.

Susceptibility rates for first- and second-generation tetracycline-class drugs against common gram-positive pathogens [27,28].

Organism Antibiotica MIC (µg/mL)
% Susceptible / % Resistant
50% 90% CLSI EUCAST
Streptococcus pneumoniae Tetracycline 0.5 >8 73.2 / 26.7 73.2 / 26.7
Doxycycline 0.25 8 71.3 / 26.8 73.9 / 24.7
Minocycline NR NR 71.7 / 27.3b 72.7 / 26.4
Streptococcus pyogenes Tetracycline ≤0.25 >8 80.3 / 19.7 79.6 / 19.7
Doxycycline 0.12 8 81.2 / 16.0 80.2 / 18.8
Minocycline NR NR 78.0 / 20.7 78.0 / 22.0
Methicillin-resistant Staphylococcus aureus Tetracycline ≤0.25 2 91.2 / 8.0 88.1 / 9.0
Doxycycline 0.12 1 96.2 / 0.6 93.5 / 5.5
Minocycline NR NR 97.2 / <0.1 88.3 / 11.3

CLSI: Clinical and Laboratory Standards Institute; EUCAST: European Committee on Antimicrobial Susceptibility Testing; MIC: minimum inhibitory concentration; NR: not recorded.

aTetracycline is considered a first-generation tetracycline-class drug. Doxycycline and minocycline are second-generation tetracycline-class drugs.

bUsing CSLI 2013 susceptibility breakpoint for doxycycline of ≤0.25 μg/mL applied to the minocycline.